Isis Pharma Our Top Biotech Tuesday September 23, 9:57 am ET By Jason Napodano, CFA
Isis Pharmaceuticals, Inc. (NasdaqGM: ISIS - News) is a drug discovery and development company focused on the therapeutic target RNA and developing products from RNA-based technologies, such as antisense. Antisense drugs are the first class of drugs targeted to control expression of genes through interactions with RNA. Beyond antisense, Isis scientists have created another technology that exploits their knowledge of RNA.
We are reiterating or rating on Isis Pharmaceuticals of a Buy and increasing our price target to $22. We believe that antisense technology represents an exciting and potentially revolutionary platform for developing therapeutic candidates to treat a wide margin of diseases. In our view, antisense as a platform is today where biologics were ten years ago.
The company's leading candidates are mipomersen (w/Genzyme GENZ) for high cholesterol and ISIS-113715 for diabetes, along with several other proprietary and partnered programs for oncology, inflammatory disease, asthma, and viral infections. Our financial model forecasts profitability in 2011.